March 23, 2009        Page 1 

CURRICULUM VITAE

Name: Peter E. Clark, M.D. Education:

September 1, 1989 - Harvard Medical School June 9, 1994 Boston, MA

Doctor of Medicine

September 1, 1985 - May 28, 1989 Cornell University

Ithaca, NY Bachelor of Arts, Biology

cum laude Postdoctoral Training:

July 1, 2000 - University Southern California June 30, 2002 Department of Urology Kenneth Norris Comprehensive Cancer Center 1441 Eastlake Avenue, MS74, Suite 7416

Los Angeles, CA Urologic oncology fellowship Advisor: Donald G. Skinner, M.D.

July 1, 1994 - Cleveland Clinic Foundation June 30, 2000 Cleveland, OH

Urology residency Advisor: Andrew C. Novick, M.D. Specialty Certi

fication:

June 30, 2002 Fellowship in Urologic Oncology March 10, 2004 Board Certified w/ American Board of Urology

Academic Appointments:

September 1, 1989 - Harvard Medical School June 1, 1994 Boston, MA July 1, 1994 - Resident

June 30, 2000 Cleveland Clinic Foundation Cleveland, OH

Clark, Peter E., M.D. Curriculum Vitae Page 2

July 1, 2000 - Fellow in Urologic Oncology June 30, 2002 University Southern California

Los Angeles, CA

August 1, 2002 - Assistant Professor of Surgery (Urology) August 13, 2006 Department of Urology

Wake Forest University School of Medicine Winston-Salem, NC

August 14, 2006 - Assistant Professor, Urologic Surgery Present Vanderbilt University Medical Center Nashville, TN April 1, 2009 Associate Professor, Urologic Surgery Present Vanderbilt University Medical Center Nashville, TN

Hospital Appointments:

2002-2006 North Carolina Baptist Hospital

Winston-Salem, NC 27157 2006-Present Vanderbilt University Hospital Nashville, TN 37232 2006-Present Veterans Administration

Tennessee Valley Health Care System Nashville Campus Nashville, TN 37212

2006-Present Meharry Medical College Nashville, TN 37208

2006-2008 Baptist Hospital Nashville, TN 37236

Professional Organizations: American Urological Association, Inc. Southeastern Section American Urological Association, Inc.

Eastern Cooperative Oncology Group

July 7, 2009

Clark, Peter E., M.D. Curriculum Vitae Page 3 Society of Urologic Oncology Founding Member: Young Urologic Oncologists (part of the Society of Urologic Oncology) Society for Basic Urologic Research Professional Activities:

Intramural: Hospital, School, Medical Center Committees:

2004-2006 Protocol Review Committee of The Comprehensive Cancer Center of Wake Forest University

2002-2006 Clinical Cancer Research Program of The

Comprehensive Cancer Center of Wake Forest University

2005-2006 Associate in the Wake Forest Institute of Regenerative Medicine

2006-Present Urology Clinical Trials Working Group, Vanderbilt University Medical Center 2006-Present Member of Elliot Newman Society

Vanderbilt Physician Scientist Development (VPSD) 2008-Present Cancer Committee for Vanderbilt Ingram Cancer Center

Extramural:

Committees/Organizations

2002-2006 Cancer and Leukemia Group B

2006-Present Eastern Cooperative Oncology Group Study Section:

1. NCCN Bladder Cancer Panel Meeting, Participant. Philadelphia, PA, June 6, 2008.

2. Rapid Access to Intervention Development (RAID) program reviewer, May 24, 2006.

July 7, 2009

Clark, Peter E., M.D. Curriculum Vitae Page 4

3. American Urologic Association Foundation Research Scholars Program review, October 6, 2007.

4. Speaker and participant at North Carolina Advisory Committee on Cancer

Coordination and Control’s Early Detection Subcommittee on “PSA screening”, October 22, 2004.

5. Participant, Research Council Strategic Planning Meeting (American Urological

Association), Baltimore, MD, August 24-25, 2007.

Editorial Appointments/Boards:

1. The Scientific World Journal: Urology Domain: Editorial Board Member Advances in Urology: Associate Editor Urology “Gold Journal”: Consulting Editor

2. The Journal of Urology, Investigative Urology Section Editorial Committee,

January 2009-December 2012.

3. Cancer and Cancer Cytopathology, Guest Editor, Renal Cell Carcinoma supplement, Spring 2009.

Reviewer for: Journal of Urology UROLOGY Digital Urology Journal European Urology Urologic Oncology: Seminars and Original Investigations Cancer Therapy The Scientific World Journal Indian Journal of Cancer World Journal of Surgical Oncology BioMed Central (BMC) BJU International Nature Clinical Practice Urology Expert Review of Anticancer Therapy Clinical Chemistry Nutrition and Cancer British Journal of Cancer CANCER The Lancet Expert Opinion on Investigational Drugs Expert Opinion on Pharmacotherapy International Urology and Nephrology

Ad hoc Reviewing:

July 7, 2009

Clark, Peter E., M.D. Curriculum Vitae Page 5

Reviewer for the 2008 AUA Guidelines Panel: “2008 Guideline for the Management of the Incidentally-Discovered Small Renal Mass.”

Moderator:

Abstract Review Team Leader: Kidney Cancer: Basic Research. 2007 Annual Meeting of the American Urological Association Podium Session #15: Kidney Cancer: Basic Research (III). 2007 Annual Meeting of the American Urological Association Abstract Review Team Leader: Kidney Cancer: Basic Research. 2008 Annual Meeting of the American Urological Association Abstract Review Team Leader: Kidney Cancer: Basic Research. 2009 Annual Meeting of the American Urological Association, Chicago, IL. Poster Session #58 Bladder Cancer: Invasive/Metastatic Disease (II), 2009 Annual Meeting of the American Urological Association, Chicago, IL. Honors and Awards:

Pregraduate Studies: High School - Captain, MVP, Lacrosse Salutatorian, St. Joseph’s High School, Metuchen, New

Jersey

Undergraduate – Cornell University Vice President, Alpha Phi Omega Service Golden Key, National Honor Society Phi Kappa Phi, National Honor Society Phi Beta Phi, National Honor Society Cornell University Dean’s List (entire undergraduate career) Undergraduate – Cornell University Vice President, Alpha Phi Omega Service

Visiting Chief Resident, University of Texas Southwestern Medical School April, 2000

July 7, 2009

Clark, Peter E., M.D. Curriculum Vitae Page 6 Honors and Awards: Outstanding Achievement in Education and Research Postgraduate Studies: Award: Wake Forest University Health Sciences

July 6, 2005 Honorable Mention: Best Reviewer for The Journal of Urology; Prostate Cancer articles, 2007. Most Outstanding Reviewer (Honorable Mention), The Journal of Urology, Prostate Cancer articles, 2008. Most Outstanding Reviewer, The Journal of Urology, Investigative Urology articles, 2009. Marquis Who’s Who in America-2009, 63rd Edition

Teaching Activities: Medical School Courses Students and PA Students: Taught medical students at Wake Forest University in Anatomy Lab, kidneys, post-abdominal wall, September 2, 2003. Anatomy Lab proctor, male/female split pelvis/perineum, Wake Forest University, School of Medicine, September 9, 2003. Speaker Wake Forest University Oncology Core Curriculum Series “Surgery for GU Cancer”, October 6, 2003. Standardized Patient Assessments Wake Forest University medical students, February 17, 2004. Anatomy lab proctor, male/female split pelvis, Wake Forest University, School of Medicine, September 7, 2004 Anatomy clinic for first year medical students, Wake Forest University, School of Medicine, September 7, 2004. Standardized Patient Assessments with medical students, Wake Forest University, School of Medicine, February 14, 2005. Standardized Patient Assessments with medical students, Wake Forest University, May 11, 2005. Anatomy clinic for first year medical students, Wake Forest University, School of Medicine, September 6, 2005. Anatomy Lab proctor, male/female split pelvis, Wake Forest University, School of Medicine, September 6, 2005.

July 7, 2009

Clark, Peter E., M.D. Curriculum Vitae Page 7 Speaker for Physician Assistant Program at Wake Forest University, School of Medicine, “A brief primer on BPH and prostate cancer”, January 20, 2006. Standardized Patient Assessments with medical students, Wake Forest University, School of Medicine, February 28, 2006. Standardized Patient Assessments with medical students, Wake Forest University, School of Medicine, May 3, 2006. Speaker at Vanderbilt University Medical Center, Department of Urologic Surgery Grand Rounds, “Diagnosis and Management of Penile Cancer”, May 4, 2007. Speaker at Vanderbilt University Medical Center, Department of Urologic Surgery Grand Rounds, “Update on the Management of Advanced Kidney Cancer”, September 21, 2007. Speaker at Vanderbilt University Medical Center, Department of Urologic Surgery Grand Rounds “Update on the Management of Advanced Kidney Cancer”, August 1, 2008. Careers in Medicine, Specialty Speed Dating event for students, Vanderbilt University Medical Center, December, 2008. Graduate School Courses: Speaker at Wake Forest University, School of Medicine, GU Surgery Grand Rounds, “Role Of Retroperitoneal Lymphadenectomy in the Management of Testicular Cancer”, October 29, 2003. Speaker at Wake Forest University, School of Medicine, GU Surgery Grand Rounds, “Controversies in Prostate Ca Screening”, January 22, 2004. Speaker at Wake Forest University, School of Medicine, GU Surgery Grand Rounds, “Kidney Cancer”, January 12, 2005. Speaker at Wake Forest University, School of Medicine, GU Surgery Grand Rounds “Update on Screening for Prostate Cancer”, October 30, 2002. “Role of Retroperitoneal Lymphadenectomy in the Management of Testicular Cancer” presented at General Surgery Grand Rounds, Wake Forest University, School of Medicine, November 27, 2002.

Speaker at Wake Forest University, School of Medicine, GU Surgery Grand Rounds, “The role of lymphadenectomy at the time of radical cystectomy for bladder cancer: is more better?”, April 9, 2003.

July 7, 2009

Clark, Peter E., M.D. Curriculum Vitae Page 8 Continuing Medical Education: (Invited Speaker) Update on Screening for Prostate Cancer presented at Wilkes Regional Medical Center, N. Wilkesboro, North Carolina, September 3, 2002. Screening for Prostate Cancer presented at Piedmont Medical Center, Rock Hill, South Carolina, October 24, 2002. Prostate Cancer Screening presented at Rowan Regional Medical Center Grand Rounds, Salisbury, North Carolina, December 5, 2002. Update on PSA Screening for Prostate Cancer presented at Grand Rounds, VA Medical Center, Salisbury, North Carolina, December 11, 2002. 32nd Annual Emery C. Miller Medical Symposium: “Prostate Cancer Update, 2002” and “Overview of Urologic Cancer for Primary Care Physicians”, August 8, 2003. Davis Regional Medical Center, “Prostate Cancer”, Statesville, North Carolina, October 14, 2003. AHEC/Community Care Center: “Update on Prostate Cancer”, January 5, 2004. Watauga Medical Center: “Update on Prostate Cancer”, March 15, 2004. 33rd Annual Emery C. Miller Medical Symposium, “BPH” and “The controversy over prostate cancer screening”, Myrtle Beach, South Carolina, August 2, 2004. CME session High Point Regional Health System, “Update on the Diagnosis and Management of Prostate Cancer”, October 12, 2004. Twin County Hospital in Galax, VA: “Bladder Cancer 2005”, February 9, 2005. Grand Rounds, Urology Center P.A., Greensboro, North Carolina, “Controversies in PSA screening for prostate cancer”, March 23, 2005. “First Annual Duke Prostate Center Symposium: Carolina Prostate Cancer Trials and Care Update”, Durham, North Carolina. “Prostate Cancer Trials at the Comprehensive Cancer Center of Wake Forest University, April 9, 2005. CME session Rowan Regional Medical Center, “Update on the Diagnosis and Management of Prostate Cancer”, November 3, 2005. CME Meeting for the Geriatrics Symposium, “Controversies in PSA Screening”, Adam’s Mark Hotel, Winston-Salem, North Carolina, February 17, 2006. Thirty-fifth Annual Emery C. Miller Medical Symposium, “Update on the Management of Prostate Cancer” and “Kidney”, Myrtle Beach, South Carolina, August 3, 2006.

July 7, 2009

Clark, Peter E., M.D. Curriculum Vitae Page 9 Faculty/Speaker, American Urologic Association Sponsored Course: “Prostate Cancer Update”, Talks entitled: “Interpretation of PSA Values”, Which Imaging Tests Help”, “Androgen Deprivation: How and How Early Should It Be Used”, & “Immunotherapy and Targeted Treatments”. San Antonio, TX, October 12-13, 2007. Thirty-fifth Annual Vanderbilt University Medical Center, Urology Society Visiting Professorship and Rhamy-Shelley Lecture, “Treatment of Advanced Renal Cell Cancer”, November 2, 2007. Speaker at CME session DeKalb Community Hospital, “Update on the diagnosis and management of Prostate Cancer”, February 4, 2008. SUO Spring Meeting, Chicago, IL, T1-3, N0 Bladder Cancer. April 25, 2009 SUO Spring Meeting, Chicago, IL. Mouse Models of Renal Carcinogenesis. April 25, 2009. Community Service/Outreach: Speaker at BestHealth: “Perplexed by Prostate Cancer”, Winston-Salem, North Carolina, August 17, 2004. Speaker at ACS sponsored community lecture: “Answering the Cancer Challenge in 2004”, November 18, 2003. Speaker, Free Prostate Cancer Screening, Downtown Health Plaza, September 22, 2005. Speaker, BestHealth: “Perplexed by Prostate Cancer”, Winston-Salem, North Carolina, May 12, 2006. Speaker, “Operative Management of Renal Masses in the VHL Patient”, VHL Connections, Nashville, Tennessee, July 21, 2007. Speaker, 86th Annual Meeting of the Clinical Society of Genitourinary Surgeons: “TRAIL Mediated Apoptosis in Advanced Renal Carcinoma”, Nashville, Tennessee, October 27, 2007. Research Program: August 2006 – Present: Vanderbilt University in the lab of Harold Moses M.D. studying mechanisms of TRAIL mediated apoptosis in renal cell carcinoma. Development of mouse models of kidney cancer and development of renal disease in collaboration with Roy Zent, M.D. August 2002 – August 2006: Wake Forest University in the lab of Andrew Thorburn, D. Phil., studying mechanisms of TRAIL mediated apoptosis in renal cell carcinoma. July 2000-July 2001: University of Southern California in the lab of Gerhard A. Coetzee, Ph.D., studying the association of the androgen receptor to endogenous promoters using a chromatin immunoprecipitation protocol.

July 7, 2009

Clark, Peter E., M.D. Curriculum Vitae Page 10 July 1997-July 1998: Cleveland Clinic Foundation in the lab of James Finke Ph.D., studying the mechanism of impaired T cell activation in patients with renal cell carcinoma. August 1992 - July 1993: Brigham and Women's Hospital in the lab of Jerome Richie MD, Chairman of the Division of Urology, studying the mechanism of action of the signaling protein, tensin. June - August 1990: Max-Planck Institute, Munich, West Germany in the lab of Walter Concha MD, studying tumor necrosis factor and interleukin-one expression in mice infected with the Coxsackie B virus. September 1988 - May 1989: Cornell University in the lab of Carl Hopkins Ph.D. studying the swimming behavior of the electric fish, Gymnotus carapo. June - August 1988: Mt. Overlook Hospital, Summit, NJ in the lab of Donald L Warkentin Ph.D. working with radialimmunoassays of human fetal hemoglobin and ELISA assays of carcinoembryonic antigen. Research Projects: Current Funding: K08 CA113452 (PI: Clark) 10/1/2005 – 9/30/2010 60% NIH/NCI $113,000/Year TRAIL Mediated Apoptosis in Renal Cell Carcinoma Study examining the role of TRAIL mediated apoptosis in renal cell carcinoma including the potential synergy between interferon alpha and recombinant TRAIL in treating RCC, the expression of TRAIL cognate death receptors, and somatic mutations in cognate TRAIL death receptors in RCC. Role: Principal Investigator Prior Funding: 1 U01 DP3000264-01 Anderson (PI) 09/30/05 – 09/29/08 1% Centers for Disease Control and Prevention annual: $ 247,970; total: $739,886 Breast and Prostate Cancer Data Quality and Patterns of Care This is a 3-year project to assess and improve data quality of North Carolina registry data for 2,000 female breast cancer cases (stages I-III) and 2,000 prostate cancer cases detected in year 2004. We will build upon our past collaborative work on patterns of care with cancer in NC by implementing data quality assessment and improvement process, and by studying patterns of care of breast cancer and prostate cancers for the total sample, by race/ethnicity groups, and by known individual poverty status. Role: Co-Investigator R21 CA113943 (PI: Arcury) 4/01/2006 – 3/31/2008 5% NIH/NCI $275,000 African American Men Prostate & Colorectal Cancer Belief The goal of this project is to document the knowledge, beliefs and behavior of African American men about prostate and colorectal cancer and screening and determine if differences between African American and white men in attitudes and behaviors about prostate and colorectal cancer screening are

July 7, 2009

Clark, Peter E., M.D. Curriculum Vitae Page 11 related to social class differences (e.g., educational attainment, income), health care access differences (e.g., health insurance, usual physician), or cultural differences (e.g., racial or ethnic specific lay concepts of health, cancer, or cancer screening). Role: Co-Investigator (no funding requested) No Grant number available 8/1/02 - 8/1/05 Comprehensive Cancer Center, Wake Forest University Young investigator start up fund from Wake Forest University Baptist Medical Center / Comprehensive Cancer Center to study cancer biology and kidney cancer Role: PI #IRG-93-035-09 12/1/02-11/30/03 American Cancer Society Institutional Research Grant DNA Damage/repair and human urinary tract cancer This study is examining DNA damage repair capacity and gene polymorphisms and the risk of bladder cancer Role: PI CA12197-29 2/1/03-1/31/04 Comprehensive Cancer Center, Wake Forest University Xenograft model testing the effect of androgen deprivation on tumors transfected wild type versus non-cleavable androgen receptor. This study examines the in vivo effect of androgen receptor proteolysis on tumor growth in a xenograft tumor model. Role: PI No Grant Number Available 2/1/05-1/30/06 Comprehensive Cancer Center, Wake Forest University Cytotoxic ODN’s for the treatment of renal cell carcinoma Intramural Partner Grant with William Gmeiner PhD looking at the potential role of FdUMP[10] as therapy for advanced kidney cancer. Role: Co-PI Clinical Studies: CCCWFU 85106 Phase II Trial of Vitamin D and Soy supplementation for Biochemically Recurrent Prostate Cancer Following Definitive Local Therapy CCCWFU ##### BARC: A Secreted Marker of Kidney Cancer Completed Studies: CCWFU 88103 DNA Damage/Repair and Human Urinary Tract Cancer.

July 7, 2009

Clark, Peter E., M.D. Curriculum Vitae Page 12 Role: Principal investigator (investigator initiated) CCCWFU 89403 Phase II Study of Intraoperative Microwave Ablation of Renal Parenchymal Tumors Prior to Nephrectomy Role: Principal Investigator (investigator initiated) Accrual Completed, manuscript in preparation CCCWFU 89C03 Bio Markers of Renal Cell Carcinoma Role: Principal Investigator (investigator initiated) Accrual Completed. CCCWFU 85A03 Bio Markers of Prostate Cancer Role: Principal Investigator (investigator initiated) Peer-reviewed Journal Articles: Capelouto CC, Clark PE, Ransil BJ, and Loughlin KR.: A review of scrotal violation in testicular cancer: is adjuvant local therapy necessary? J Urol 153(3 Pt 2): 981-985, 1995. Ling W, Rayman P, Uzzo R, Clark PE, Kim HJ, Tubbs R, Novick A, Bukowski R, Hamilton T and Finke J: Impaired activation of NFB in T cells from a subset of renal cell carcinoma patients is mediated by inhibition of phosphorylation and degradation of the inhibitor, IB. Blood 92(4): 1334-1341, 1998 Clark PE, Streem SB and Geisinger MA: Thirteen year experience with percutaneous management of upper tract transitional cell carcinoma. J Urol 161(3): 772-775, 1999. Uzzo RG, Clark PE, Rayman P A, Bloom T, Rybicki L, Novick AC, Bukowski R M and Finke J H: Alterations in NFB activation in T lymphocytes of patients with renal cell carcinoma. J Natl Cancer Inst, 91(8): 718-721, 1999. Uzzo RG, Rayman PA, Kolenko V, Clark PE, Bloom T, Ward AM, Molto L, Tannenbaum C, Worford LJ, Bukowski RM, Tubbs R, His ED, Bander NH, Novick AC and Finke JH: Mechanism of apoptosis in T cells from patients with renal cell carcinoma. Clin Ca Res 5(5): 1219-1229, 1999. Uzzo RG, Rayman PA, Kolenko V, Clark PE, Cathcart MK, Bloom T, Novick AC, Bukowski R M, Hamilton T, and Finke JH: Suppression of NFB activation in T cells by soluble products from renal cell carcinoma is mediated by tumor derived gangliosides. J Clin Inv 104(6): 769-776, 1999. Clark PE and Novick AC: Exophytic non-invasive growth pattern of renal angiomyolipomas: Implications for nephron-sparing surgery. J Urol 165(2): 513-514, 2001. Clark PE, Schover L, Uzzo RG, Hafez KS, Rybicki LA, and Novick AC: Quality of life and psychological adaptation following surgical treatment for localized renal cell carcinoma: Impact of the amount of remaining renal parenchyma. Urol 57(2): 252-256, 2001.

July 7, 2009

Clark, Peter E., M.D. Curriculum Vitae Page 13 Clark PE, Peereboom DM, Dreicer R, Levin HS, Clark SB and Klein EA: Phase II trial of estramustine phosphate and etoposide plus radical retropubic prostatectomy in patients with locally advanced prostate cancer. Urol 57(2): 281-285, 2001. Clark PE, Levin HS, Kupelian PA, Reddy C, Zippe CD, and Klein EA: Intermediate-Term Outcome with Radical Prostatectomy for Localized Prostate Cancer: The Cleveland Clinic Experience. The Prostate Journal 3(2): 118-125. 2001 Wilson SS, Clark PE, and Stein JP: Angiomylipoma with vena cava extension. Urol 60(4): 695-696, 2002. Jia L, Kim J, Shen H, Clark PE, Tilley WD, and Coetzee GA: Androgen Receptor Activity at the Prostate Specific Antigen Locus: Steroidal and Non-Steroidal Mechanisms. Mol Ca Res 1: 385-392, 2003. Quek ML, Stein JP, Clark PE, Daneshmand S, Miranda G, Cai J, Groshen S, Lieskovsky G, Quinn DI, Raghavan D, and Skinner DG: Natural History of Surgically Treated Bladder Carcinoma with Extravesical Tumor Extension. Cancer 98(5): 955-961, 2003. Clark PE, Stein JP, and Skinner DG: Radical cystectomy in the treatment of invasive bladder cancer: Role and limitations. Urol Integr Invest 8 (3) part 2/2: 240-248, 2003. Quek ML, Stein JP, Clark PE, Daneshmand S, Miranda G, Cai J, Groshen S, Cote RJ, Lieskovsky G, Quinn DI, and Skinner DG: Microscopic and gross extravesical extension in pathological staging of bladder cancer. J Urol 171(2 Pt 1): 640-645, 2004. Clark PE, Hall MC, Miller A, Ridenhour KP, Stindt D, Lovato JF, Patton SE, Brinkley W, Das S, and Torti FM. Phase II Trial of Combination Interferon Alpha and Thalidomide as First Line Therapy in Metastatic Renal Cell Carcinoma. Urol 63(6): 1061-1064, 2004. Zagoria RJ, Hawkins AD, Clark PE, Hall MC, Matlaga BR, Dyer RB, and Chen MY: Percutaneous CT-guided radiofrequency ablation of renal neoplasm: Factors influencing success and midterm results. Am J Roentgenol 183(1): 201-207, 2004. Kubinski DJ, Clark PE, Assimos DG, and Hall MC: Utility of Frozen Section Analyses of Resection Margins During Partial Nephrectomy. Urol 64(1): 31-4, 2004. Lockett KL, Hall MC, Xu J, Zheng SL, Berwick M, Chuang SC, Clark PE, Cramer SD, Lohman K, and Hu JJ: The ADRPT V762A Genetic Variant Contributes to Prostate Cancer Susceptibility and Deficient Enzyme Function. Cancer Res 64(17): 6344-6348, 2004. Clark PE, Stein JP, Groshen SG, Miranda G, Cai J, Lieskovsky G, and Skinner DG: The Management of Urethral Transitional Cell Carcinoma After Radical Cystectomy for Invasive Bladder Cancer. J Urol 172(4, part 1 of 2): 1342-1347, 2004.

July 7, 2009

Clark, Peter E., M.D. Curriculum Vitae Page 14 Clark PE, Stein JP, Groshen SG, Cai J, Miranda G, Lieskovsky G, and Skinner DG: Radical Cystectomy in the Elderly: Comparison of Survival Between Younger and Older Patients. Cancer 103(3): 546-552, 2005. Clark PE, Farver CF, Ulchaker JC, and Angermeier K: A rare case of an extra-adrenal myelolipoma arising in the renal sinus: a case report and review of the literature. Sci World Jour 5:109-117, 2005. Stein JP, Clark PE, Miranda G, Cai J, Groshen S, and Skinner DG: Urethral tumor recurrence following cystectomy and urinary diversion: Clinical and pathological characteristics of 768 patients. J Urol 173(4): 1163-1168, 2005. Clark PE, Stein JP, Groshen SG, Cai J, Miranda G, Lieskovsky G, and Skinner DG: Radical cystectomy in the elderly: Comparison of clinical outcomes between younger and older patients. Cancer 104(1): 36-43, 2005. Clark PE, Veys JA, Eskridge MR, Woodruff RD, and Hall MC: Prognostic significance of clinicopathologic and DNA flow cytometric variables in non-metastatic renal cell carcinoma in the modern era. Urol Onc 23(5): 328-332, 2005. Gwynn ES and Clark PE: A case of inflammatory myofibroblastic tumor associated with renal cell carcinoma. Urol 66(4): 880, 2005. Papagikos MA, Deguzman AF, Rossi PJ, McCullough DL, Clark PE, and Lee WR: Dosimetric quantifiers for low-dose-rate prostate brachytherapy: is V(100) superior to D(90). Brachytherapy 4(4): 252-258, 2005. Gwynn ES, Clark PE, and Hall MC: Recent Advances in the Treatment of Bladder Cancer. Expert Rev Anticancer Ther 5(6): 1023-30, 2005. Lockett K L, Hall MC, Clark PE, Chuang SC, Robinson B, Lin HY, Su J and Hu JJ.: DNA Damage Levels in Prostate Cancer Cases and Controls. Carcinogenesis 27(6):1187-1193, 2006. Rossi PJ, Clark PE, Papagikos MA, McCullough D L, and Lee WR: Percentage positive biopsies associated with freedom from biochemical recurrence following low-dose-rate prostate brachytherapy alone for clinically localized prostate cancer. Urol 67(2): 349-353, 2006. Borden LS, Clark PE, Lovato J, Hall MC, Stindt D, Harmon M, Mohler RM. and Torti FM: Vinorelbine, Doxorubicin, and Prednisone in Androgen-Independent Prostate Cancer. Cancer 107(5): 1093-1100, 2006. Clark PE, Hall MC, Borden LS Jr, Miller A A, Hu J, Lee WR, Stindt D, D’Agostino R Jr, Lovato J, Harmon M, and Torti FM: A Phase I-II Prospective Dose-Escalating Trial Of Lycopene In Patients With Biochemical Relapse Of Prostate Cancer After Definitive Local Therapy. Urol 67(6): 1257-61, 2006. Papagikos MA, Rossi PJ, Urbanic JJ, deGuzman AF, McCullough DL, Clark PE, Lee WR.: A Simple Model Predicts Freedom From Biochemical Recurrence After Low-Dose Rate Prostate Brachytherapy Alone. Am J Clin Oncol 30(2): 199-204, 2007.

July 7, 2009

Clark, Peter E., M.D. Curriculum Vitae Page 15 Clark PE, Woodruff RD, Zagoria RJ, and Hall MC.: Microwave ablation of renal parenchyma tumor before nephrectomy: phase I study. Am J Rad 188(5): 1212-4, 2007. Phillips JJ, Hall MC, Lee WR., and Clark PE: Does a delay in initiating therapy affect biochemical recurrence rates in men with clinically localized prostate cancer? Urol Onc 25(3): 196-200, 2007. Heilbrun ME, Zagoria RJ, Garvin AJ, Hall MC, Krehbiel K, Southwick A, Clark PE.: CT-guided biopsy for the diagnosis of renal tumors before treatment with percutaneous ablation. AJR Am J Roentgenol 188(6): 1500-5, 2007. Yacoub J, Richardson C, Farmer M, Lee WR, Clark PE, Hurt G, and Levine EA: Male breast cancer during treatment with leuprolide for cancer of the prostate. Clin Adv in Hem & Onc 5(7): 1-2, 2007. Lowrance WT, Cookson MS, Clark PE, Smith JA Jr, Chang SS: Assessing retroperitoneal lymphadenectomy experience in U.S. urologic residency programs. J Urol 178(2): 500-503, 2007. Zagoria RJ, Traver MA, Werle DM, Perini M, Hayasaka S, and Clark PE: Oncologic Efficacy of CT-Guided Percutaneous Radiofrequency Ablation of Renal Cell Carcinomas. AJR 189(2):429-436, 2007. Bin L, Thorburn J, Thomas LR, Clark PE, Humphreys R, and Thorburn A: Tumor-derived mutations in the TRAIL receptor DR5 inhibit TRAIL signaling through the DR4 receptor by competing for ligand binding. J Biol Chem 282(38): 28189-28194, 2007. Patel SG, Cookson MS, Clark PE, Smith JA Jr, and Chang S: Neovesical-urethral anastomotic stricture after orthotopic urinary diversion: presentation and management. BJU International 101: 219-222, 2007. Smith JA Jr, Chan RC., Chang SS, Herrell SD, Clark PE, Baumgartner R, and Cookson MS: A Comparison of the Incidence and Location of Positive Surgical Margins in Robotic Assisted Laparoscopic Radical Prostatectomy and Open Retropubic Radical Prostatectomy. J Urol 178 (6): 2385-2389, 2007. Barbieri CE, Lee B, Cookson MS, Bingham J, Clark PE, Smith JA Jr, Chang SS: Association of procedure volume with radical cystectomy outcomes in a nationwide database. J Urol 178(4 Pt 1): 1418-1421, 2007. Lowrance WT, Rumohr JA, Change SS, Clark PE, Smith JA Jr, and Cookson MS: Contemporary Open Radical Cystectomy: Analysis of Perioperative Outcomes. J Urol 179(4):1313-1318, 2008. Zabaleta J, Lin HY, Sierra RA, Hall MC, Clark PE, Sartor O, Hu JJ, and Ochoa AC: Interactions of Cytokine Gene Polymorphisms in Prostate Cancer Risk. Carcinogenesis (3):573-578, 2008. Chan RC, Barocas DA, Chang SS, Herrell SD, Clark PE, Baumgartner R, Smith JA Jr, and Cookson MS: Effect of a large prostate gland on open and robotically assisted laparoscopic radical prostatectomy. BJU Int 101(9):1140-1144, 2008.

July 7, 2009

Clark, Peter E., M.D. Curriculum Vitae Page 16 Stec AA, Coons BJ, Chang SS, Cookson MS, Herrell SD, Smith JA Jr, and Clark.PE: Waiting Time from Initial Urological Consultation to Nephrectomy for Renal Cell Carcinoma: Does it Affect Survival? J. Urol 179(6): 2152-2157, 2008. Koski ME, Tedesco JM, and Clark PE: Renal peripheral neuroectodermall tumor presenting at age 78: Case report. Sci World Jour, 8: 830-834, 2008. Rossi PJ, Urbanic J, Clark PE, McCullough DL, Lee WR. Pretreatment prostate-specific antigen velocity is associated with freedom and biochemical recurrence of prostate cancer after low-dose-rate prostate brachytherapy alone. Brachytherapy. 2008 Oct-Dec;7(4):286-9. Patel SG, Cookson MS, Clark PE, Smith JA Jr, and Chang SS. Neovesical-urethral anastomotic stricture after orthotopic urinary diversion: presentation and management. BJU Int. Jan;101(2):219-22, 2008. Rossi PJ, Urbanic J, Clark PE, McCullough DL, and Lee WR: Pretreatment PSAV is associated with freedom from biochemical recurrence of prostate cancer following low dose rate prostate brachytherapy alone. Brachytherapy 7 286-289, 2008. Coons BJ, Clark PE, Maynes LJ, Terhune KP, Stokes MC, and Beech DJ: Sigmoid-Urachal-Cutaneous Fistula in an Adult Male. Urol. In Press. Winterich JA, Quandt SA, Gryzwacz JG, Clark PE, Miller DP, Acuna J, and Arcury TA: Masculinity and the Body: How African-American and White Men Experience Cancer Screening Exams Involving the Rectum. Am J Men’s Health. July 22, 2008. In Press. Lewis JE, Soler-Vila H, Clark PE, Kresty LA, Allen GO, and Hu JJ: Intake of Plant Foods and Associated Nutrients in Prostate Cancer Risk. Nutr Cancer. 2009;61(2):216-24. Blum DA, Koyama T, M’Koma AE, Iturregui JM, Martinez-Ferrer M, Uwamariya C, Smith JA Jr, Clark PE, and Bhomick NA: Chemokine Markers Predict Biochemical Recurrence of Prostate Cancer Following Prostatectomy. Clin Cancer Res. 2008 Dec 1;14(23):7790-7. Boudreaux KJ, Clark PE, Lowrance WT, Rumohr JA, Barocas DA, Cookson MS, Smith JA Jr, and Chang SS: A Comparison of American Joint Committee on Cancer Pathologic Stage T2a versus T2b urothelial carcinoma: Analysis of patient outcomes in organ confined bladder cancer. J Urol, 2009 Feb;181(2):540-5. Boudreaux KJ, Chang SS, Lowrance WT, Rumohr JA, Barocas DA, Cookson MS, Smith JA Jr, and Clark PE: A Comparison of American Joint Committee on Cancer Pathologic Stage T3a versus T3b urothelial carcinoma: Analysis of patient outcomes. Cancer. 2009 Feb 15;115(4):770-5.

Coons BJ, Stec AA, Stratton KL, Chang SS, Cookson MS, Herrell SD, Smith JA Jr, Clark PE . Prognostic Factors in T3b Renal Cell Carcinoma. World J Urol. 2009 Feb;27(1):75-9.

July 7, 2009

Clark, Peter E., M.D. Curriculum Vitae Page 17 Winterich JA, Grzywacz JG, Quandt SA, Clark PE, Miller DP, Acuña J, Dignan MB, Arcury TA. Men’s Knowledge and Beliefs about Prostate Cancer: Education, Race, and Screening Status. Ethn & Dis.2009 Spring;19(2):199-203. In press. Lowrance WT, Rumohr JA, Clark PE, Chang SS, Smith JA Jr, Cookson MS. Trends in Urinary Diversion from a High Volume, Single US Tertiary Care Center. Journal of Urology. In press. Jovanny Zabaleta, L. Joseph Su, Hui-Yi- Lin, Rosa A. Sierra, M. Craig Hall, Oliver A. Sartor, Clark PE, Jennifer J. Hu, Augusto C. Ochoa. Cytokine gene polymorphisms and prostate cancer aggressiveness. Carcinogenesis. In press, 2009. Mitchell RE, Lee BT, Cookson MS, Barocas DA, Herrell SD, Clark PE, Smith JA, Chang SS. Radical nephrectomy surgical outcomes in the University HealthSystem Consortium Data Base: Impact of Hospital Case Volume, Hospital Size, and Geographic Location on 40,000 Patients. Cancer. 2009 Mar 23. In press. Patel SG, Cookson MS, Barocas DA, Clark PE, Smith JA Jr, Chang SS. Risk factors for urothelial carcinoma of the prostate in patients undergoing radical cystoprostatectomy for bladder cancer. BJU Int. 2009 Mar 18. In press. Invited Reviews Journal Articles: Clark PE and Streem SB: Endourologic management of upper tract transitional cell carcinoma. AUA Update Series, 18: 122, 1999. Clark PE and Klein EA: Surgery for invasive bladder tumors: technique and outcome. Curr Opinion Uro, 9(5): 413-418, 1999. Clark PE and Streem SB: What is the role of percutaneous management in upper-tract TCC? Contemp Urol 13: 66-71, 2001. Clark PE: Urinary Diversion after Radical Cystectomy. Curr Treat Options in Oncol 3(5): 389-402, 2002 Clark PE, Irvine RA, and Coetzee GA: The androgen receptor CAG repeat and prostate cancer risk. Methods Mol Med 81: 255-66, 2003. Borden LS, Clark PE, and Hall MC: Bladder cancer. Curr Opin Oncol 15(3):227-233, 2003. Clark PE and Torti FM: Prostate Cancer and Bone Metastases. Medical Treatment. Clin Orthop 415 (Suppl): S148-157, 2003 Matlaga BR, Zagoria RJ, Clark PE, and Hall MC: Radiofrequency ablation of renal tumors. Curr Urol Rep 5(1): 39-44, 2004

July 7, 2009

Clark, Peter E., M.D. Curriculum Vitae Page 18 Matlaga BR, Clark PE, and Hall MC: Reducing prostate biopsy pain: Options for effective analgesia. Contemp Urol 16(3): 74-80, 2004. Borden LS, Clark PE, and Hall MC: Bladder Cancer. Curr Opin Oncol 16(3): 257-262, 2004 Clark PE and Streem SB: Endourologic management of upper tract transitional cell carcinoma. Sci World Jour 4(S1): 62-75, 2004. Borden LS, Clark PE, and Hall MC: Bladder Cancer. Curr Opin Oncol 17(3): 275-280, 2005. Clark PE and Hall MC: Contemporary management of the urethra in patients with radical cystectomy for bladder Cancer. Urol Clin North Am 32(2): 199-206, 2005. Clark PE, Stein JP, Groshen SG, Miranda G, Cai J, Lieskovsky G, and Skinner DG: Case Illustrations on Managing Urethral Carcinoma Recurrence After Cystectomy, Am J Urol Rev 3(6): 274-278, 2005. Gwynn ES and Clark PE.: Bladder Cancer. Curr Opin Oncol 18(3): 277-283, 2006. Rackley JD, Clark PE, and Hall MC: Complementary and Alternative Medicine in the Treatment of Prostate Cancer. Urol Clin N Amer 33 (2): 237-246, 2006. Clark PE, Hall MC, and Lee WR: Lycopene Dietary Supplements and Prostate Cancer Treatment. Sem Prev and Alt Med 2(2): 72-75, 2006. Clark PE: Bladder Cancer, Cur Op Onc 19(3): 241-7, 2007. Clark PE: Recent Advances in targeted therapy for renal cell carcinoma: Curr Op Urol 17:331-336, 2007. Barocas DA and Clark PE: Bladder Cancer. Curr Opin Oncol 20(3):307-314, 2008. Clark PE and Cookson MS: The von-Hippel Lindau gene: turning discovery into therapy. Cancer, 113(S7): 1768-1778, 2008. Montie JE, Clark PE, Eisenberger MA, El-Galley R, Greenberg RE, Herr HW, Hudes GR, Kuban DA, Kuzel TM, Lange PH, Lele SM, Michalski J, Patterson A, Pohar KS, Richie JP, Sexton WJ, Shipley WU, Small EJ, Trump DL, Walther PJ, Wilson TG. Bladder Cancer. J Natl Compr Canc Netw. Jan;7(1):8-39, 2009.

Bischoff CJ, Clark PE. Bladder Cancer. Curr Opin Oncol. 2009 May;21(3):272-7.

Clark PE. Neoadjuvant versus adjuvant chemotherapy for muscle-invasive bladder cancer. Expert Rev Anticancer Ther. 2009 Jun;9(6):821-830.

Electronic Publications:

July 7, 2009

Clark, Peter E., M.D. Curriculum Vitae Page 19

July 7, 2009

Clark PE and Streem,SB: Endourologic management of upper tract transitional cell carcinoma. Dig J

rol U http://www.duj.com/Article/Streem.html. Clark PE: Diagnosis of BPH (prostatism). UrologyHealth.org 2003, http://www.urologyhealth.org/ Quek ML, Stein JP, Clark PE, Daneshmand S, et al.: Natural History of Surgically Treated Bladder Carcinoma with Extravesical Tumor Extension. 2003 American Cancer Society Published online www.interscience.wiley.com. Monographs and Textbooks: Assisted in the writing, compilation, and editing of a student initiated textbook "Pathophysiology of Heart Disease", Lea and Febiger, Philadelphia, 1993. Clark PE and Stein JP: Cystectomy in the Elderly. In: Urothelial Tumors, ed. Droller, M., BC Decker Hamilton, 2004, pp. 272-289. Clark PE, Stein JP, and Skinner DG: La cistectomia radical en el cancer vesical infiltrate. In: Cancer De Vejiga, Historia Natural / Biologia / Terapeutica., ed. Angulo, J. and Berenguer, A., Schering Espana, S.A., Madrid, 2004, pp. 357-368. Abstracts/Scientific Exhibits: Clark PE Kifor I, Dluhy R and Vickers M: Modulation of angiotensin II secretion in single human corpora cavernosa cells exposed to prostaglandin E1 orpapaverine. New England section of the American Urologic Association (NE AUA), 62: abstract 9, 1993. Clark PE Capelouto C and Loughlin K: A review of scrotal violation in testicular carcinoma: is adjuvant local therapy necessary. New England section of the American Urologic Association (NE AUA), 62: abstract 56, 1993. Rosenberg M, Clark PE and O'Donnel M: Intravesical use of recombinant interleukin-2 secreting BCG on superficial bladder cancer in a rat model. New England section of the American Urologic Association (NE AUA), 62: abstract 54, 1993. Hattori T, Lu M, Summerhayes I, Clark PE, Leder P and Richie JP: The characterization of prostatic cell lines derived from an int-2 transgenic mouse and from a normal mouse: an in vitro model of int-2 regulated prostatic cell growth. Accepted for publication in the 1993 Surgical Forum. Clark PE and Streem SB: Twelve year experience with percutaneous management of upper tract transitional cell carcinoma. North Central Section of the American Urologic Association (NCS AUA) 71: 42, 1997. Clark PE, Kupelian P, Klein E and Zippe C: Importance of initial tumor/patient characteristics in predicting survival in patients with localized prostate cancer failing radiotherapy. J Urol 157: 1121A, 1997.

Clark, Peter E., M.D. Curriculum Vitae Page 20 Clark PE, Montie JE and Klein EA: Long term follow up of renal function and upper tract status in adults after ileal conduit urinary diversion for pelvic malignancy. North Central Section of the American Urologic Association (NCS AUA) 72: 42, 1998. Clark PE and Streem SB: Thirteen year experience with the percutaneous management of upper tract transitional cell carcinoma. J Urol 159: 752A, 1998. Rayman P, Clark PE, Uzzo RG, Novick AC, Bukowski RM and Finke JH: Impaired T cell activation in a subset of patients with renal cell carcinoma is secondary to impaired degradation of IBβ or IB J Urol 159: 767A, 1998. Uzzo RG, Clark PE, Rayman P, Klein E, Bukowski R, Novick AC and Finke JH: Evidence that tumor suppresses NFΚB activation in T cells of patients with renal cell carcinoma. J Urol 159: 572A, 1998. Kolenko V, Uzzo RG, Clark PE, Rayman P, Bukowski R, Tubbs R, Novick AC and Finke JH: Characterization of CD95/CD95L expression and apoptosis in T cells of patients with renal cell carcinoma (RCC). J Urol 159: 657A, 1998. Clark PE, Uzzo RG, Rayman P, Novick AC, Bukowski R, and Finke J: Impaired T cell activation in a subset of patients with renal cell carcinoma may be secondary to impaired degradation of IBβ. Proc Am Assoc Cancer Res 39: abstract 4173, 1998. Ling W, Rayman P, Uzzo RG, Clark PE, Bloom T, Kim HJ, Hamilton T, Tubbs R, Novick A, Bukowski R, and Finke J.: Impaired activation of NFB in T cells from a subset of renal cell carcinoma (RCC) patients involves nuclear degrading of RelA. Proc Am Assoc Cancer Res 39: abstract 578, 1998. Kolenko VM, Uzzo RG, Rayman PA, Clark PE, Bukowski R, Tubbs R, Novick AC, and Finke J: T cell induced apoptosis in renal cell carcinoma. Proc Am Assoc Cancer Res 39: abstract 3608, 1998. Clark PE, Uzzo RG, Novick AC and Schover LR: Quality of life after partial nephrectomy or radical nephrectomy for renal cell carcinoma. North Central section of the American Urologic Association (NCS AUA) 73: 39, 1999. Clark, PE, Montie JE and Klein EA: Long term follow up of renal function and upper tract status after ileal conduit urinary diversion. J Urol 161: 247A, 1999. Uzzo RG, Rayman P, Clark PE, Kolenko V, Bukowski R, Novick AC and Finke J: Inhibition of NFB binding in T cells of patients with renal cell carcinoma (RCC): The role of immunosuppresive gangliosides. J Urol 161: 520A, 1999. Uzzo RG, Rayman P, Kolenko V, Clark PE, Cathcart M, Bloom T, Novick AC, Bukowski RM, Hamilton T and Finke JH: Tumor-induced inhibition of NFB activation in the presence of normal IB degradation: the role of immunosuppressive gangliosides. Proc Am Assoc Cancer Res 40: 513, 1999.

July 7, 2009

Clark, Peter E., M.D. Curriculum Vitae Page 21 Uzzo RG, Rayman P, Kolenko V, Clark PE, Cathcart M, Bloom T, Novick AC, Bukowski RM, Hamilton T and Finke JH: Gangliosides derived from renal cell carcinoma can inhibit NFB activation in the presence of normal IB degradation. Presented at Northeast Regional Cancer Consortium, Feb. 26, 1999. Clark PE, Schover LR, Uzzo RG, Hafez KS, Rybicki LA and Novick AC: Quality of life and psychological adaptation following surgery for localized renal cell carcinoma: Impact of the amount of remaining renal tissue. J Urol 163: 700A, 2000. Klein EA, Clark PE, Zippe CD, Levin HS and Kupelian P: Intermediate term (8 year) outcome after radical retropubic prostatectomy for T1/T2 prostate cancer-The Cleveland Clinic Experience. J Urol 163: 1495A, 2000. Clark PE, Irvine RA, Park JJ, Press MF, and Coetzee GA: The role of BRCA1 in androgen receptor signaling in prostate cancer cell lines. Presented at Western Section American Urological Association Meeting, Anchorage, AL, Sept. 18 2001. Clark PE, Stein JP, Miranda G, Lieskovsky G, and Skinner DG: The management of urethral transitional cell carcinoma after radical cystectomy for invasive disease. Presented at Western Section American Urological Association Meeting, Anchorage, AL, Sept. 18 2001. Clark PE, Irvine RA, Park JJ, Press MF, and Coetzee GA: The role of BRCA1 in androgen receptor signaling in prostate cancer cell lines. J Urol 167:208A, 2002. Clark PE, Stein JP, Miranda G, Lieskovsky G, and Skinner DG: The management of urethral transitional cell carcinoma after radical cystectomy for invasive disease. J Urol 167:1032A, 2002. Clark PE, Stein JP, Groshen SG, Cai J, Miranda G, Lieskovsky G, and Skinner DG: Cystectomy in the elderly for transitional cell carcinoma. J Urol 167:1040A, 2002. Stein JP, Clark PE, Miranda G, Groshen S, Cai J, Lieskovsky G, and Skinner DG: Risk factors for patients with pelvic lymph node metastases following radical cystectomy with en bloc pelvic lymphadenectomy. J Urol 167:1120A, 2002. Stein JP, Clark PE, Miranda G, Dunn M, Skinner E, Lieskovsky G, and Skinner DG: Results with the antirefluxing T-limb: Does it work? J. Urol 169:238A, 2003. Dunn MD, Stein JP, Skinner DG, and Clark PE: Endoscopic management of afferent nipple valve stenosis in patients with the Kock pouch urinary diversion: Long-term results with the Acucise endopyelotomy balloon. J Urol 169:296A, 2003. Clark PE, Hall MC, Kidenhour KP, Stindt D, Paton SE, Brinkley W, Das S, and Torti FM. Phase II Trial of Combination Interferon Alpha and Thalidomide as First Line Therapy in Metastatic Renal Cell Carcinoma. J Urol 169:901A, 2003.

July 7, 2009

Clark, Peter E., M.D. Curriculum Vitae Page 22 Clark PE, Stein JP, Miranda G, Groshen SG, Cai,J, Lieskovsky G, and Skinner DG. Thirty year experience with radical cystectomy after high dose pelvic irradiation. J Urol 169:DP4, 2003. Veys JA, Eskridge MR, Woodruff RD, Clark PE, and Hall MC: Prognostic significance of clinicopathologic and DNA flow cytometric variables in non-metastatic renal cell carcinoma in the modern era. J Urol 169:781A, 2003. Kubinski,D, Clark PE, Assimos DG, Hopkins MB, and Hall MC: Utility of Frozen Section Analyses of Resection Margins During Partial Nephrectomy. Abstract Presentation at the SESAUA March 2004. Matlaga BR, Hudson J, Clark PE, Zagoria RJ, and Hall MC: Percutaneous, Water-Cooled Radiofrequency Ablation of Renal Cell Carcinoma. Abstract Presentation at the SESAUA March 2004. Clark PE, Hall MC, Miller A, Ridenhour KP, Stindt D, Patton SE, Brinkley W, Das S, and Torti FM: Phase II Trial of Combination Interferon Alpha and Thalidomide as First Line Therapy in Metastatic Renal Cell Carcinoma. Abstract Presentation at the SESAUA, March 2004. Veys JA, Eskridge MR, Woodruff RD, Clark PE, Hall MC. Prognostic Significance of Clinicopathologic and DNA Flow Cystometric Variables in Non-Metastatic Renal Cell Carcinoma in the Modern Era. Abstract Presentation at the SESAUA, March 2004. Kubinski DJ, Clark PE, Assimos DG, Hopkins MB, and Hall MC: Utility of frozen section analyses of resection margins during partial nephrectomy. J Urol 171(4S): 30A, 2004. Stein JP, Clark PE, Cai,J., Groshen S, Miranda G, Skinner DG: Urethral tumor recurrence following cystectomy and urinary diversion: Clinical and pathological characteristics in 768 patients. J Urol 171(4S): 306A, 2004. Clark PE, Stindt D, Hall MC, Harmon M, Lovato JF, Mohler R, Kimbrough C, and Torti FM: Phase II trial of gemcitabine, paclitaxel, and cisplatin in advanced transitional cell carcinoma. Proceedings of ASCO, 23: 4610A, 2004. Clark PE, Hall MC, Lockett K, Phillips JJ, Xu J, Zheng S, Chuang S, and Hu J: DNA-Repair genetic polymorphisms and prostate cancer. Society of Urologic Oncology 2004 Annual Meeting. Phillips J, Clark PE, Hall MC, Lockett K, Xu J, Zheng S, Chuang S, and Hu J: DNA-Repair genetic polymorphisms and prostate cancer aggressiveness. Abstract # 23 69th annual meeting of the Southeastern Section of the American Urological Association, March 2005. Clark PE, Hall MC, Lockett K, Xu J, Zheng S, Chuang S, and Hu J: DNA-Repair genetic polymorphisms and prostate cancer risk. Abstract # 34 69th annual meeting of the Southeastern Section of the American Urological Association, March 2005. Borden L, Clark PE, Lovato J, Stindt D, Hall MC, Bivens A, Johnson R, and Torti FM: Vinorelbine (Navelbine), doxorubicin (adriamycin), and prednisone (NAP) in androgen-independent prostate cancer. Abstract # 26 69th annual meeting of the Southeastern Section of the American Urological Association, March 2005.

July 7, 2009

Clark, Peter E., M.D. Curriculum Vitae Page 23 Kubinski D, Clark PE, Veys J, Strang A and Hall MC: Utility of routine bladder biopsy in patients with negative cystoscopy and urinary cytology after induction BCG fro high risk superficial bladder cancer. Abstract # 39 69th annual meeting of the Southeastern Section of the American Urological Association, March 2005. Clark PE, Stindt D, Hall MC, Harmon M, Lovato J, Mohler R, Kimbrough C, and Torti FM: Phase II trial of gemcitabine, paclitaxel, and cisplatin in advanced transitional cell carcinoma. Abstract # 43 69th annual meeting of the Southeastern Section of the American Urological Association, March 2005. Borden L, Clark PE, Miller A, Lee WR, Hu J, Stindt D, Torti FM, and Hall MC: Prospective dose-escalation trial of lycopene in men with recurrent prostate cancer following definitive local therapy. Abstract # 103 69th annual meeting of the Southeastern Section of the American Urological Association, March 2005. Clark PE, Hall MC, Lockett KL, Xu J, Zheng SL, Chuang, S., and Hu, J.: DNA-Repair Genetic Polymorphisms and Prostate Cancer Risk. J Urol 173 (4S): 259A, 2005. Clark PE, Gyabaah K, and Thorburn AM: Synergistic Killing of Renal Cell Carcinoma Cells by Interferon Alpha and Tumor Necrosis Factor (TNF) Related Apoptosis Inducing Ligand (TRAIL). J Urol 173 (4S): 632A, 2005. Borden L, Clark PE, Miller A, Lee WR, Hu J, Stindt D, Torti FM, and Hall, M. C.: Prospective Dose-Escalation Trial Of Lycopene In Men With Recurrent Prostate Cancer Following Definitive Local Therapy. J Urol 173 (4S): 1014A, 2005. Clark PE, Stindt D, Hall MC, Harmon M, Lovato J, Mohler R, Kimbrough C, and Torti FM: Phase II Trial Of Gemcitabine, Paclitaxel, And Cisplatin In Advanced Transitional Cell Carcinoma. J Urol 173 (4S): 1326A, 2005. Clark PE, Woodruff RD, Zagoria RJ, and Hall MC: Phase II Prospective Evaluation of a Novel Microwave Ablation System for Renal Masses During Radical Nephrectomy. J Urol 173 (4S): 1333A, 2005. Clark PE, Hall MC, Borden L, Miller A, Hu J, Lee WR, Stindt D, D’Agostino R, Lovato J, and Torti FM.: A Phase I/II Prospective Dose Escalating Trial Of Lycopene In Patients With Biochemical Relapse Of Prostate Cancer Following Definitive Local Therapy. Society for Urologic Oncology Annual Meeting, 2005. Gwynn E, Clark PE, and Hall MC: Fluorescence In Situ Hybridization versus urinary cytology in the surveillance of superficial bladder cancer. Abstract # 3 70th annual meeting of the Southeastern Section of the American Urological Association, March 2006. Clark PE, Gyabaah K, and Thorburn A: Synergistic killing of renal cell carcinoma cells by interferon alpha and tumor necrosis factor (TNF) related apoptosis inducing ligand (TRAIL). Abstract # 10 70th annual meeting of the Southeastern Section of the American Urological Association, March 2006.

July 7, 2009

Clark, Peter E., M.D. Curriculum Vitae Page 24 Traver M, Werle D, Clark PE, Zagoria R, Helibrun M, and Hall MC: Complications of radiofrequency ablation (RFA) of renal neoplasms: a single institution experience. Abstract # 15 70th annual meeting of the Southeastern Section of the American Urological Association, March 2006. Phillips J, Clark PE, and Hall MC: Open radical retropubic prostatectomy: A benchmark for recent innovative approaches to prostate cancer treatment. Poster # 25 70th annual meeting of the Southeastern Section of the American Urological Association, March 2006. Phillips J, Clark PE, Lee WR, and Hall MC: Does a delay in initiating definitive therapy affect biochemical recurrence rates in men with clinically localized prostate cancer? Abstract # 69 70th annual meeting of the Southeastern Section of the American Urological Association, March 2006. Traver MA, Werle DM, Clark PE, Zagoria R, Helibrun ME, and Hall MC: Oncologic efficacy and factors influencing the success of computerized tomography (CT) guided percutaneous radiofrequency ablation (RFA) of renal neoplasms. Poster # 51 70th annual meeting of the Southeastern Section of the American Urological Association, March 2006. Traver MA, Werle DM, Clark PE, Zagoria RJ, Helibrun ME, and Hall MC: Oncologic efficacy and factors influencing the success of computerized tomography (CT) guided percutaneous radiofrequency ablation (RFA) of renal neoplasms. J Urol 175 (4S): 1120A, 2006. Rumohr JA, Lowrance WT, Chang SS, Smith JA Jr, Cookson MS, and Clark PE: Examining contemporary urinary diversion: A review of changing practice patterns diversion selectivity. J Urol 177 (4S): 178A, 2007. Tikhonenkov SN, Wells N, Dutta S, Clark T, Chang SS, Clark PE, and Cookson MS: Prospective Assessment of health related quality of life (HRQOL) at one year following radical cystectomy and urinary diversion. J Urol 177 (4S): 574A, 2007. Barbieri CE, Lee B, Cookson MS, Smith JA Jr, Clark PE, and Chang SS: Association of procedure volume with radical cystectomy outcomes in a nationwide database. J Urol 177 (4S): 1513A, 2007. Welty CJ, Chang SS, Clark PE, Smith JA Jr, and Cookson MS: The influence of histopathologic method on prostatic carcinoma incidence and Gleason Grade in cystoprostatectomy specimens. J Urol 177 (4S): 1648A, 2007. Barocas DA, Chang SS, Clark PE, Patel SG, Smith JA Jr, and Cookson MS Outcomes of patients undergoing radical cystoprostatectomy for bladder cancer with prostatic involvement on final pathology. Poster # 60, Society for Urologic Oncology Annual Meeting, 2007. Barocas DA, Chang SS, Clark PE, Patel SG, Smith JA Jr, and Cookson MS: Outcomes of patients undergoing radical cystoprostatectomy for bladder cancer with prostatic involvement on final pathology. Abstract #308, Genitourinary Cancers Symposium, 2008. Barocas DA, Lea WB, Clark PE, Chang SS, Herrell SD, Smith JA Jr, and Cookson MS: Utilization of systemic therapy for patients undergoing cytoreductive nephrectomy as a component of multi-modal therapy for renal cell carcinoma. Abstract #379, Genitourinary Cancers Symposium 2008.

July 7, 2009

Clark, Peter E., M.D. Curriculum Vitae Page 25 Chan R, Barocas DA, Chang SS, Herrell SD, Clark PE, Baumgartner R, Smith JA Jr, and Cookson MS: Robotic-assisted versus open radical retropubic prostatectomy in obese and non-obese patients. Poster #23 72nd Annual Meeting of the Southeaster Section of the American Urological Association, March 2008. Chan R, Barocas DA, Cookson MS, Herrell SD, Clark PE, Baumgartner R, Smith JA Jr, and Chang SS: Prostate volume and high grade prostate cancer in robotic and open radical retropubic prostatectomy. Poster #56 72nd Annual Meeting of the Southeaster Section of the American Urological Association, March 2008. Stec AA, Coons BJ, Chang SS, Cookson MS, Herrell SD, Smith JA Jr, and Clark PE: Waiting time from diagnosis to nephrectomy for renal cell carcinoma: Does it affect survival? Podium #60 72nd Annual Meeting of the Southeastern Section of the American Urological Association, March 2008. Patel SG, Chang SS, Barocas DA, Clark PE, Smith JA Jr, and Cookson MS: Outcomes of patients undergoing radical cystoprostatectomy for bladder cancer with prostatic involvement on final pathology. Podium #89 72nd Annual Meeting of the Southeastern Section of the American Urological Association, March 2008. Rumohr JA, Whittam B, Cookson MS, Chang SS, Smith JA Jr., and Clark PE: Radical cystectomy in the elderly: Outcomes in a large contemporary series. Podium #95 72nd Annual Meeting of the Southeaster Section of the American Urological Association, March 2008. Welty CJ, Chang SS, Lowrance WT Thomasch J, Clark PE, Smith JA Jr, and Cookson MS: The influence of histopathologic method on prostatic carcinoma incidence in cystoprostatectomy specimens. Podium #103 72nd Annual Meeting of the Southeastern Section of the American Urological Association, March 2008. Mitchell RE, Lee BT, Cookson MS, Barocas DA, Herrell SD, Clark PE, Smith JA Jr, and Chang S: Immediate surgical outcomes for radical prostatectomy in the university healthsystem consortium database: The impact of hospital case volume, hospital size, and geographic region on 48,000 patients. J Urol 179 (4S): 466A, 2008. Mitchell RE, Lee BT, Cookson MS, Barocas DA, Herrell SD, Clark PE, Smith JA Jr, and Chang SS: Radical nephrectomy surgical outcomes in the university healthsystem consortium database: The impact of hospital case volume, hospital size and geographic location on 40,000 patients. J Urol 179 (4S): 467A, 2008. Barocas DA, Lea WB, Clark PE, Chang SS, Herrell SD, Smith JA Jr, and Cookson MS: Utilization of systemic therapy in patients undergoing cytoreductive nephrectomy as a component of multi-modal therapy for renal cell carcinoma. J Urol 179 (4S): 959A, 2008. Barocas DA, Lea WB, Clark PE, Chang SS, Herrell SD, Smith JA Jr, and Cookson MS: Survival outcomes in patients undergoing cytoreductive nephrectomy as a component of multi-modal therapy for renal cell carcinoma. J Urol 179 (4S): 1103A, 2008.

July 7, 2009

Clark, Peter E., M.D. Curriculum Vitae Page 26 Stec AA, Coons BJ, Lowrance WT, Chang SS, Cookson MS, Herrell SD, Smith JA Jr, and Clark PE: Waiting time from diagnosis to nephrectomy for renal cell carcinoma: Does it affect survival? J Urol 179 (4S): 1210A, 2008. Lund L, Jacobsen J, Clark PE, Borre M, Norgaard M, and Sorensen HT: The impact of comorbidity on survival of invasive bladder cancer patients, 1995-2004: A Danish population-based cohort study. J Urol 179 (4S): 1556A, 2008. Patel SG, Cookson MS, Clark PE, Barocas DA, Smith JA Jr, and Chang SS: Risk factors for urothelial carcinoma of the prostate in patients undergoing radical cystoprostatectomy for bladder cancer. J Urol 179 (4S): 1557A, 2008. Boudreaux KJ, Chang SS, Lowrance WT, Rumohr JA, Barocas DA, Cookson MS, Smith JA Jr, and Clark PE: A comparison of American Joint Committee on Cancer pathologic stage T3a versus T3b urothelial cancer: analysis of patient outcomes. Cancer 2009 Jan 17. Boudreaux KJ, Clark PE, Lowrance WT, Rumohr JA, Barocas DA, Cookson MS, Smith JA Jr and Chang SS: A comparison of American Joint Committee on Cancer pathologic stage T2a versus T2b urothelial cancer: Analysis of patient outcomes in organ confined bladder cancer. J Urol 2009 Feb;181 (2):540-5 1692A. Stratton K, Stec AA, Coons BJ, Chang SS, Cookson MS, Herrell SD, Barocas DA, Smith JA Jr , Clark PE. Thrombocytosis As A Predictor Of Survival After Nephrectomy For Renal Cell Carcinoma. Podium #80, SESAUA 73rd Annual Meeting, March 2009. Humphrey J, Stimson CJ, Chang SS, Clark PE, Barocas DA, Patel SG, Smith JA Jr, Cookson MS. Preoperative Hydronephrosis Predicts Extravesical And Node Positive Disease Prior To Cystectomy. Podium #96, SESAUA 73rd Annual Meeting, March 2009. Humphrey J, Stimson BS, Chang SS, Clark PE, Barocas DA, Patel SG, Smith JA Jr, Cookson MS. Analysis Of Hospital Readmission Rates Within 90 Days Following Cystectomy. Podium #97, SESAUA 73rd Annual Meeting, March 2009. Barocas DA, Patel SG, Cookson MS, Welty CJ, Clark PE, Smith JA Jr, and Chang SS. Smoking Cessation In Patients Undergoing Radical Cystectomy For Bladder Cancer. Podium #100, SESAUA 73rd Annual Meeting, March 2009. Barocas DA, Chang SS, Clark PE, Mishra V, Chan R, Herrell SD, Baumgartner R, Smith JA Jr, Cookson MS. Comparison Of Transfusion Requirements Between Open and Robotic Assisted Laparoscopic Radical Prostatectomy. Podium #109, SESAUA 73rd Annual Meeting, March 2009. Barocas DA, Patel SG, Chang SS, Clark PE, Smith JA Jr, Cookson MS. Urothelial Carcinoma Of The Bladder With Mixed Histology: Is This A Bad Actor? Poster #36, SESAUA 73rd Annual Meeting, March 2009.

July 7, 2009

Clark, Peter E., M.D. Curriculum Vitae Page 27 Kaufman MR, Dietrich MS, Clark PE, Barocas DA, Chang SS, Davis R, Cookson MS, Smith JA Jr, Herrell SD. Identification Of Distinct Outcomes Clusters For Urinary Function Following Radical Prostatectomy . Podium #10, AUA Annual Meeting, April 2009. Kaufman MR, Dietrich MS, Clark PE, Barocas DA, Chang SS, Davis R, Cookson MS, Smith JA Jr Herrell SD. Relationship Of Urinary Function Following Radical Prostatectomy With Medical Comorbidities And Global Quality Of Life Parameters. Podium #239, AUA Annual Meeting, April 2009. Barocas DA, Salem S, Kordan Y, Herrell SD, Chang SS, Clark PE, Davis R, Phillips S, Cookson MS, Smith JA Jr. Comparison of 3-Year Cancer Control Outcomes In Robotic-Assisted Laparoscopic Prostatectomy (RALP) Versus Radical Retropubic Prostatectomy (RRP) For Prostate Cancer. Podium #1278, AUA Annual Meeting, April 2009. Coons BJ, Stec AA, Stratton KL, Herrell SD, Chang SS, Cookson MS, Smith JA Jr, Clark PE. Prognostic Factors In T3B Renal Cell Carcinoma. Podium #1384, AUA Annual Meeting, April 2009. Stimson CJ, Humphrey JE, Patel SG, Clark PE, Barocas DA, Chang SS, Smith JA Jr, Cookson MS. Analysis Of Early And Late Hospital Readmissions Following Radical Cystectomy. Podium #1749, AUA Annual Meeting, April 2009. Kordan Y, Salem S, Chang SS, Clark PE, Cookson MS, Davis R, Herrell SD, Phillips S, Smith JA Jr, Barocas DA. Impact Of Positive Apical Surgical Margins (SM) On The Likelihood of Biochemical Recurrence (BCR) After Prostatectomy. Podium #1853, AUA Annual Meeting, April 2009. Newton M, Cookson MS, Chan R, Chang SS, Clark PE, Davis R, Herrell SD, Mishra V, Phillips S, Smith JA Jr, Barocas DA. Relationship Between Prostate Volume And Pathologic Grade Of Prostate Cancer. Podium #1963, AUA Annual Meeting, April 2009. Lectures, Speeches, Exhibits, Films: SPORE Grant presented at the Wake Forest University School of Medicine Comprehensive Cancer Center Lay Advisory Board Meeting, Winston-Salem, NC, October 9, 2002. Professor/Invited lecturer XXVII Annual meeting of Colegio Mexicano de Urologia, talks on “Radical Cystectomy in the Treatment of Invasive Bladder Cancer” and “The Management of Superficial Bladder Cancer”, Morelia Mexico, March 18-22, 2003. Fourth International Galician Urological Meeting, Cracow, Poland. “The role of lymphadenectomy at the time of radical cystectomy for bladder cancer: is more better?” Krakow Poland, November 8, 2003. Comprehensive Cancer Center Clinical Research Annual Retreat “Novel Strategies in Prostate Cancer”, November 19, 2003. Wake Forest University.

July 7, 2009

Clark, Peter E., M.D. Curriculum Vitae Page 28

July 7, 2009

Prostate Cancer Center of Excellence Retreat: “Dose Escalating Phase II Trial of Lycopene for Biochemical Relapse of Prostate Cancer Following Definitive Local Therapy”, April 20, 2004. Update on Screening for Prostate Cancer presented at Wilkes Regional Medical Center, N. Wilkesboro, NC, September 3, 2002.